放射性碘难治性分化型甲状腺癌再分化治疗研究进展  

Progress in the study of redifferentiation therapy for radioactive iodine-refractory differentiated thyroid carcinoma

作　　者：刘晶 张俊[2] Liu Jing;Zhang Jun(Graduate School,Dalian Medical University,Dalian 116044,China;Department of Nuclear Medicine,Affiliated Jiangsu Taizhou People's Hospital of Nanjing Medical University,Taizhou 225300,China)

机构地区：[1]大连医科大学研究生院,大连116044 [2]南京医科大学附属泰州人民医院核医学科,泰州225300

出　　处：《国际肿瘤学杂志》2024年第7期464-467,共4页Journal of International Oncology

摘　　要：分化型甲状腺癌总体预后良好,但仍有少部分患者会出现局部复发和远处转移,在初始或治疗过程中丧失摄碘能力,成为放射性碘难治性分化型甲状腺癌(RAIR-DTC),预后较差。RAIR-DTC患者治疗方法有限,且效果欠佳,通过药物促进再分化使RAIR-DTC恢复摄碘能力是治疗的重要策略之一。The overall prognosis of differentiated thyroid cancer is good,but a small number of patients will still develop local recurrence and distant metastasis,and lose iodine uptaking ability in the initial or treatment process,becoming radioactive iodine-refractory differentiated thyroid carcinoma(RAIR-DTC),with a poor prognosis.Treatment options for RAIR-DTC patients are limited with poor results,and restoration of iodine uptaking capacity in RAIR-DTC through pharmacological promotion of redifferentiation is one of the important strategies for treatment.

关 键 词：碘放射性同位素 甲状腺肿瘤 细胞去分化 分子靶向治疗 

分 类 号：R736.1[医药卫生—肿瘤]